Cyclooxygenase inhibitors not inhibit resting lung cancer A549 cell proliferation

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 74, Issue 5, 2006, Pages 317-321

  Duan, Weigang ^a   Zhang, Luyong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; LIPOPOLYSACCHARIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL ACTIVITY; CELL PROLIFERATION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; LUNG CANCER; MEMBRANE STEADY POTENTIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ASPIRIN; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EICOSANOIC ACIDS; HUMANS; ISOENZYMES; LIPOPOLYSACCHARIDES; LUNG NEOPLASMS; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 33646457964     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2006.02.006     Document Type: Article

References (31)

1. Mao J.T., Roth M.D., Serio K.J., et al. Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. Clin. Cancer Res. 9 16 Pt 1 (2003) 5835-5841
2. Shaik M.S., Chatterjee A., Jackson T., and Singh M. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int. J. Cancer (2005) [Epub ahead of print]
3. Xing L., Zhang Z., Xu Y., Zhang H., and Liu J. The effects of nimesulide combined with cisplatin on lung cancer. J. Huazhong Univ. Sci. Technolog. Med. Sci. 24 2 (2004) 120-123
4. Choudhury Q.G., McKay D.T., Flower R.J., and Croxtall J.D. Investigation into the involvement of phospholipases A(2) and MAP kinases in modulation of AA release and cell growth in A549 cells. Br. J. Pharmacol. 131 2 (2000) 255-265
5. Proulx L.I., Gaudreault M., Turmel V., Augusto L.A., Castonguay A., and Bissonnette E.Y. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone, a component of tobacco smoke, modulates mediator release from human bronchial and alveolar epithelial cells. Clin. Exp. Immunol. 140 1 (2005) 46-53
6. Jung Y.J., Isaacs J.S., Lee S., Trepel J., and Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17 14 (2003) 2115-2117
7. Sweeney F.J., Wachtmann T.S., Eskra J.D., et al. Inhibition of IL-1beta-dependent prostaglandin E2 release by antisense microsomal prostaglandin E synthase 1 oligonucleotides in A549 cells. Mol. Cell Endocrinol. 205 1-2 (2003) 151-157
8. Newton R., Cambridge L., Hart L.A., Stevens D.A., Lindsay M.A., and Barnes P.J. The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes. Br. J. Pharmacol. 130 6 (2000) 1353-1361
9. Sievers E.M., Bart R.D., Backhus L.M., Lin Y., et al. Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of lung cancer for dose-dependent effect. J. Thorac. Cardiovasc. Surg. 129 6 (2005) 1242-1249
10. Singh R.P., Mallikarjuna G.U., Sharma G., et al. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin. Cancer Res. 10 24 (2004) 8641-8647
11. Wu S., Duan S., Zhao S., Cai Y., Chen P., and Fang X. Atorvastatin reduces lipopolysaccharide-induced expression of cyclooxygenase-2 in human pulmonary epithelial cells. Respir. Res. 6 1 (2005) 27
12. Knight D.A., Asokananthan N., Watkins D.N., Misso N.L., Thompson P.J., and Stewart G.A. Oncostatin M synergises with house dust mite proteases to induce the production of PGE(2) from cultured lung epithelial cells. Br. J. Pharmacol. 131 3 (2000) 465-472
13. Patel R.N., Attur M.G., Dave M.N., et al. A novel mechanism of action of chemically modified tetracyclines: inhibition of COX-2-mediated prostaglandin E2 production. J. Immunol. 163 6 (1999) 3459-3467
14. Watkins D.N., Garlepp M.J., and Thompson P.J. Regulation of the inducible cyclo-oxygenase pathway in human cultured airway epithelial (A549) cells by nitric oxide. Br. J. Pharmacol. 121 7 (1997) 1482-1488
15. Mitchell J.A., Belvisi M.G., Akarasereenont P., et al. Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br. J. Pharmacol. 113 3 (1994) 1008-1014
16. Chang M.S., Chen B.C., Yu M.T., Sheu J.R., Chen T.F., and Lin C.H. Phorbol 12-myristate 13-acetate upregulates cyclooxygenase-2 expression in human pulmonary epithelial cells via Ras, Raf-1, ERK, and NF-kappaB, but not p38 MAPK, pathways. Cell Signal 17 3 (2005) 299-310
17. Catley M.C., Chivers J.E., Cambridge L.M., et al. IL-1beta-dependent activation of NF-kappaB mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. FEBS Lett. 547 1-3 (2003) 75-79
18. Duan W., Yu Y., and Zhang L. Antiatherogenic effects of Phyllanthus Emblica associated with Corilagin and its Analogue. Yakugaku Zasshi 5 7 (2005) 587-591
19. Asano K., Lilly C.M., and Drazen J.M. Prostaglandin G/H synthase-2 is the constitutive and dominant isoform in cultured human lung epithelial cells. Am. J. Physiol. 271 1 Pt 1 (1996) L126-L131
20. Hung W.C., Chang H.C., Pan M.R., Lee T.H., and Chuang L.Y. Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol. Pharmacol. 58 6 (2000) 1398-1403
21. Denkert C., Kobel M., Berger S., et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 61 1 (2001) 303-308
22. Castano E., Bartrons R., and Gil J. Inhibition of cyclooxygenase-2 decreases DNA synthesis induced by platelet-derived growth factor in Swiss 3T3 fibroblasts. J. Pharmacol. Exp. Ther. 293 2 (2000) 509-513
23. Yang P., Chan D., Felix E., et al. Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. J. Lipid Res. 45 6 (2004) 1030-1039
24. Bagga D., Wang L., Farias-Eisner R., Glaspy J.A., and Reddy S.T. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc. Natl. Acad. Sci. USA 100 4 (2003) 1751-1756
25. Fukumoto K., Yano Y., Virgona N., et al. Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth. FEBS Lett. 579 17 (2005) 3829-3836
26. Morosetti R., Servidei T., Mirabella M., et al. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int. J. Oncol. 25 2 (2004) 493-502
27. Avis I., Martinez A., Tauler J., et al. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res. 65 10 (2005) 4181-4190
28. Peter S.P., Leslie G.C., Maryanne D., Gillian E.C., and Michael J.J. Differential Regulation of Prostaglandin E2 and Thromboxane A2 Production in Human Monocytes: implications for the use of cyclooxygenase inhibitors. J. Immunol. 165 3 (2000) 1605-1611
29. Chen X.L., Su B.S., Sun R.Q., Zhang J., and Wang Y.L. Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma. World J. Gastroenterol. 11 8 (2005) 1228-1231
30. Stavreus-Evers A., Koraen L., Scott J.E., Zhang P., and Westlund P. Distribution of cyclooxygenase-1, cyclooxygenase-2, and cytosolic phospholipase A2 in the luteal phase human endometrium and ovary. Fertil. Steril. 83 1 (2005) 156-162
31. Guan Y., Zhang Y., Andre S., et al. Urogenital distribution of a mouse membrane-associated prostaglandin E2 synthase. Am. J. Physiol. Renal. Physiol. 281 (2001) F1173-F1177